The New Era of Weight Loss: From Willpower to Metabolic Science
For the past 50 years, the global weight-loss industry has relied on one core assumption: if people just had more willpower, they would lose weight.
Diet plans, detox programs, calorie-counting apps, meal replacements, and endless fitness trends have all been built around this belief. Eat less. Move more. Try harder.
Yet despite decades of advice and billions spent on weight-loss products, obesity rates have continued to rise worldwide. The reason is becoming clearer: weight loss was never purely a willpower problem. Biology plays a real, measurable part in it too. Advances in metabolic science are finally starting to change how that gets treated.
We asked Dr Shyamala Vishnumohan (Dr Shy), PhD, APD, a food scientist and Accredited Practising Dietitian specialising in GLP-1 nutrition, whether it's accurate to call this a shift from willpower to biology.
I would be a little careful about calling obesity a hormonal condition. It is much more complex than that. Hormones are part of the picture, but so are the brain, genetics, sleep, environment, behaviour and many other factors.
We have actually known for decades that GLP-1 affects appetite and fullness. What changed was our ability to develop medicines that could use that biology in a much more powerful and sustained way.
For many years, the conversation around weight focused heavily on eating less, moving more and having enough willpower. These medicines have really challenged that idea. That doesn't mean behaviour doesn't matter. Of course it does. But behaviour doesn't happen in isolation from biology. It is very different trying to make a food decision when you are comfortably satisfied compared with trying to make that same decision when your brain is constantly telling you to eat.
— Dr Shyamala Vishnumohan (Dr Shy), PhD, APD
That's a more accurate framing than a clean "willpower versus biology" split, and it's worth holding onto through the rest of this piece: what's changed isn't that biology suddenly started mattering. It's that medicine finally built tools that work with it.
Note: Dr Shy contributed independent expert commentary to this article. She has no commercial relationship or affiliation with Caddy and does not endorse Caddy or its products.
The Last 50 Years of Weight Loss: A Willpower Experiment
Most weight-loss strategies over the last few decades have followed the same formula, focusing almost entirely on behavioural control — calorie restriction, low-carb or low-fat diets, detox programs, intermittent fasting, intense exercise routines.
While these methods can work for some people short term, they often fail to deliver sustainable long-term results. The human body has powerful systems that regulate hunger, metabolism, and energy balance. When people reduce calories drastically, the body typically responds by increasing hunger signals, slowing metabolism, and conserving energy. This biological response makes weight loss extremely difficult to sustain.
For decades, the failure of these approaches was framed as a failure of discipline, not a limitation of the tools themselves.
Understanding GLP-1: The Hormone Behind the Breakthrough
The modern shift in obesity treatment comes from understanding a key hormone involved in appetite regulation: Glucagon-Like Peptide-1, or GLP-1.
GLP-1 is a hormone naturally released in the body after eating. It signals the brain that you're full, slows stomach emptying, helps regulate blood sugar, and reduces appetite. In people struggling with obesity, these signals may not function as effectively.
GLP-1 medications work by enhancing these natural biological pathways, helping the body regulate appetite and satiety more effectively. Instead of fighting biology, these treatments work with it.
Researchers first identified GLP-1 in 1986, as an unexpected fragment of a hormone precursor called proglucagon. It took nearly four decades from that discovery to the medications now reshaping obesity treatment — which is exactly the gap Dr Shy's answer above addresses: the biology was known for a long time before the tools to act on it existed.
The Evolution of GLP-1 Medications
The science of GLP-1 therapies has advanced rapidly over the past decade. Each new generation of drugs improves how the body regulates hunger and metabolism.
Semaglutide: The GLP-1 Agonist
Medications like Ozempic and Wegovy contain semaglutide, which acts as a GLP-1 receptor agonist — it mimics the effects of the natural GLP-1 hormone. Semaglutide works by reducing appetite, increasing feelings of fullness, slowing digestion, and improving blood sugar regulation. Clinical trials have shown it can produce significant weight loss when combined with lifestyle changes.
Tirzepatide: The Dual Agonist
The next major advancement came with tirzepatide, marketed as Mounjaro (and as Zepbound for weight management). Unlike semaglutide, tirzepatide targets two metabolic pathways — GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) — simultaneously.
The numbers back up the "dual agonist, bigger effect" claim: in the SURMOUNT-1 trial, tirzepatide produced average weight loss of 16.0% to 22.5% depending on dose, well above what single-pathway semaglutide typically achieves. A later head-to-head trial, SURMOUNT-5, confirmed tirzepatide outperforms semaglutide directly over 72 weeks.
Retatrutide: The Triple Agonist
The next frontier in metabolic medicine is retatrutide — a triple agonist targeting three hormonal pathways: GLP-1, GIP, and glucagon. This combination aims to influence both appetite regulation and energy expenditure.
Retatrutide has now completed its core Phase 3 program. In the TRIUMPH-1 trial, participants on the highest dose lost an average of 28.3% of body weight at 80 weeks — meaningfully ahead of tirzepatide's SURMOUNT-1 results. Eli Lilly has said it plans to file for FDA approval in early 2027. It remains investigational and isn't available by prescription anywhere yet.
We asked Dr Shy what people should realistically expect from a triple-agonist drug:
Retatrutide is exciting because it works on three hormone receptors — GLP-1, GIP and glucagon — rather than GLP-1 alone, or GLP-1 and GIP as tirzepatide does.
The weight-loss results reported so far are certainly impressive. In the Phase 3 TRIUMPH-1 trial, Lilly reported average weight loss of 28.3% at 80 weeks at the highest dose. But retatrutide is still an investigational medicine, and we are still waiting for the head-to-head trial comparing it directly with tirzepatide. So I think we need to be careful about turning this into a competition about which drug produces the biggest number on the scales.
From my perspective as a dietitian, the more powerful these medications become, the more important nutrition becomes too. If somebody's appetite drops dramatically and they are eating much less, I want to know what they are actually managing to eat. Are they getting enough protein? Are they drinking enough? Are their bowels okay? Are they maintaining their strength? Are they getting enough nutrition from a much smaller amount of food?
I don't think the goal should ever be, "How little can I eat?" The goal is to get the health benefits of treatment while protecting muscle, strength, nutrition and the ability to function well in everyday life.
— Dr Shy, PhD, APD
Dr Louis Lerebours, MD, a family medicine physician and lead doctor at Freeman Recovery Center, echoes the caution on getting ahead of the science: early results are genuinely significant, but retatrutide remains experimental, and patients shouldn't treat approval — or personal success with it — as a foregone conclusion.
For the day-to-day mechanics — nausea, protein targets, fibre — our guide to preventing GLP-1 side effects covers it in more depth.
Why GLP-1 Is Not a Shortcut
One of the most common criticisms of GLP-1 medications is that they're somehow a "shortcut" to weight loss. This misunderstands how these treatments work.
GLP-1 medications don't eliminate the need for healthy habits. People using these therapies still need to focus on balanced nutrition, physical activity, and sustainable lifestyle changes. What GLP-1 treatments do is reduce the biological resistance to weight loss — they help regulate appetite and satiety signals so people can maintain healthier eating patterns more easily.
In that sense: it's not cheating, it's not a shortcut, it's progress. Just as modern medicine developed treatments for hypertension, diabetes, and cholesterol, metabolic medicine is now advancing to support weight management.
We asked Dr Shy what the biggest misconception is about how these drugs actually work:
One of the biggest misconceptions is that they simply slow the stomach down and make you feel full. That is part of the story, particularly early in treatment, but it is not the whole story.
These medicines also influence the communication between the gut and the brain. They affect systems involved in hunger, fullness and the way we respond to food. That is why patients sometimes describe something much more interesting than simply saying, "I get full faster." They might tell me they are thinking about food less. The chocolate in the cupboard isn't calling to them in quite the same way. They can leave food on the plate without having to argue with themselves about it. Some people describe that as their "food noise" becoming quieter. That is a very different experience from simply having more willpower.
But there is another side to it that I talk about with my patients all the time. We don't want appetite suppression to become appetite elimination. When someone tells me, "It's working really well because I can hardly eat," I don't automatically see that as a success. Your appetite may have changed, but your body still needs to be nourished. And when you are eating less, what you do manage to eat becomes even more important.
— Dr Shy, PhD, APD
Why Some Industries Have Pushed Back on GLP-1
Every major treatment breakthrough disrupts existing systems, and GLP-1 is no exception. For decades, an entire ecosystem grew around weight loss — diet programs, detox products, weight-loss supplements, crash diet plans, "miracle" fat-burning foods — built on repeated attempts rather than resolution.
As GLP-1 medications become more medically effective and more affordable, some of these business models face real disruption. That's a straightforward market dynamic, not a scandal — and it doesn't mean every critique of GLP-1 is self-interested. Some concerns, like the muscle-loss and nutrition risks Dr Shy raises above, are entirely legitimate and worth taking seriously regardless of who's making the point.
The Future of Weight Loss
The rise of GLP-1 therapies marks a real shift in how obesity is understood and treated — not a clean jump from willpower to biology, but a widening of what's understood to matter, and better tools to act on it.
This doesn't mean lifestyle choices stop mattering. Dr Shy's point stands: behaviour doesn't happen in isolation from biology, and nutrition matters more, not less, once appetite suppression enters the picture. For millions of people who have struggled with weight despite years of effort, that combination — real biological tools, used alongside real nutritional support — is what represents the actual breakthrough.
Know what you ate. Know how much.
Score 8. Lose weight. That's it.
Get Caddy — built to handle the nutrition side of GLP1 treatments: tracking protein, fibre and overall intake accurately while your appetite is being medically managed, so "eating less" stays "eating well" instead of just less.
If you're weighing whether a GLP-1 makes sense for you, check your eligibility before starting — the criteria differ for Indian body types, and it's worth five minutes. If you're already on one, our GLP-1 diet plan for India covers what to eat around it in more detail.
Sources
Frequently Asked Questions
- Is obesity really just a hormonal condition?
- Not quite — it's more accurate to say hormones are one major factor among several, alongside brain chemistry, genetics, sleep, environment and behaviour. GLP-1 medications work because they act on a real hormonal pathway, but that doesn't reduce obesity to a single biological switch.
- How long has GLP-1 been known to science?
- GLP-1 was first identified in 1986, nearly four decades before the current generation of GLP-1 medications reached the market. The delay was less about discovering the hormone and more about developing medicines stable enough to use it therapeutically.
- Is tirzepatide (Mounjaro) really more effective than semaglutide (Ozempic)?
- Trial data supports this. In head-to-head testing, tirzepatide produced greater average weight loss than semaglutide over 72 weeks, consistent with tirzepatide acting on two hormonal pathways (GLP-1 and GIP) rather than one.
- What is retatrutide, and is it available yet?
- Retatrutide is an investigational triple-agonist medication targeting GLP-1, GIP and glucagon. In trials, the highest dose produced 28.3% average weight loss at 80 weeks — ahead of currently approved options. It has completed Phase 3 testing, but it is not FDA-approved and isn't available by prescription; Eli Lilly plans to file for approval in early 2027.
- Do these medications remove the need to think about food or nutrition?
- No — if anything, nutrition becomes more important once appetite drops sharply. With less food intake overall, getting enough protein, fibre and hydration from what you do eat matters more, not less.
Get Caddy
Your simplest way to eat smarter with Indian food
Download